Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

In English

Författare

  • Antonio Palumbo
  • Anders Waage
  • Cyrille Hulin
  • Meral Beksac
  • Sonja Zweegman
  • Francesca Gay
  • Peter Gimsing
  • Xavier Leleu
  • Pierre Wijermans
  • Gulsan Sucak
  • Sara Pezzatti
  • Gunnar Juliusson
  • Brigitte Pegourie
  • Martijn Schaafsma
  • Monica Galli
  • Ingemar Turesson
  • Brigitte Kolb
  • Bronno van der Holt
  • Ileana Baldi
  • Jurgen Rolke
  • Giovannino Ciccone
  • Marc Wetterwald
  • Henk Lokhorst
  • Mario Boccadoro
  • Philippe Rodon
  • Pieter Sonneveld
Visa allt

Summary, in English

Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a major source of morbidity. A meta-analysis of data from individual patients (n=1680) in six randomized trials was performed, comparing the effects of melphalan-prednisone-thalidomide versus melphalan-prednisone. The main objective was to estimate the risk of serious adverse events and their impact on outcome. The primary endpoints were the 2-year cumulative incidence of grade 3-4 hematologic and non-hematologic toxicities. At least 75% of the grade 3-4 toxicities occurred during the first 6 months of treatment in both treatment groups. The cumulative incidence of grade 3-4 hematologic toxicities was higher in the melphalan-prednisone-thalidomide group than in the melphalan-prednisone group (28% versus 22%; HR 1.32, 95% CI 1.05-1.66) as was the cumulative incidence of non-hematologic toxicities (39% versus 17%, HR 2.78, 95% CI 2.21-3.50). Grade 3-4 non-hematologic toxicities were significantly increased in patients with poor Performance Status. Occurrence of grade 3-4 non-hematologic toxicities had a negative impact on both progression-free survival (HR 1.24, 95% CI 1.07-1.45) and overall survival, (HR 1.23, 95% CI 1.03-1.47). Besides toxicities, progression-free and overall survival were also negatively affected by advanced International Staging System stage, high creatinine levels and poor Performance Status. Age had a negative impact on survival as well. Although melphalan-prednisone-thalidomide improved outcome, it increased toxicities, especially non-hematologic ones. Serious non-hematologic toxicities, older age, poor Performance Status, and high creatinine levels negatively affected survival. (C) 2013 Ferrata Storti Foundation. This is an open-access paper. doi: 10.3324/haematol.2012.067058

Publiceringsår

2013

Språk

Engelska

Sidor

87-94

Publikation/Tidskrift/Serie

Haematologica

Volym

98

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Ferrata Storti Foundation

Ämne

  • Hematology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1592-8721